Combining proteasome inhibition with a targeted therapy directed against the entire B-cell lineage, including immature cells, such as BTK inhibition, is a rational strategy to simultaneously treat both, the proteasome inhibitor-sensitive mature myeloma cells and the proteasome inhibitor-resistant immature cell populations. Here, BTK is linked to plasma cell myeloma.